The KCNJ6 antibody is a crucial tool in studying the KCNJ6 gene, which encodes the G protein-activated inward rectifier potassium channel 2 (GIRK2 or Kir3.2). This protein is part of the inwardly rectifying potassium channel family (Kir3), known for regulating cellular excitability by mediating potassium efflux in response to G protein-coupled receptor (GPCR) activation. KCNJ6 is widely expressed in the brain, heart, and other tissues, playing roles in neuronal signaling, cardiac rhythm modulation, and neurotransmitter release.
Antibodies targeting KCNJ6 are used to detect its expression, localization, and function in research settings. They are critical in elucidating KCNJ6's involvement in neurological disorders (e.g., epilepsy, Down syndrome, and addiction mechanisms) and cardiac pathologies. Commercially available KCNJ6 antibodies are typically validated for applications like Western blotting, immunohistochemistry, and immunofluorescence.
Dysregulation of KCNJ6 has been linked to diseases such as Keppen-Lubinsky syndrome, a rare condition characterized by developmental delays and metabolic abnormalities. Research using KCNJ6 antibodies also explores its interaction with signaling molecules (e.g., βγ subunits of G proteins) and its role in synaptic plasticity. As Kir channels are potential therapeutic targets, these antibodies aid in drug discovery and mechanistic studies. Quality validation, including specificity checks via knockout controls, is essential to ensure reliable experimental outcomes.